| Dr Kimberly Hamilton, MD | |
|
1 Medical Center Dr, Morgantown, WV 26506-1200 | |
| (304) 598-6127 | |
| Not Available |
| Full Name | Dr Kimberly Hamilton |
|---|---|
| Gender | Female |
| Speciality | Neurosurgery |
| Experience | 12 Years |
| Location | 1 Medical Center Dr, Morgantown, West Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639439508 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 1639439508 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Virginia University Hospitals | Morgantown, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| West Virginia University Medical Corporation | 1052224565 | 1613 |
News Archive
Warner Chilcott plc today announced a 20,000,000 share secondary offering of its ordinary shares by certain selling shareholders. The selling shareholders include funds affiliated with Bain Capital Partners, DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP Capital) and Thomas H. Lee Partners, L.P., certain other institutional investors and members of the Company's senior management. The offering is being conducted as a public offering pursuant to an effective shelf registration statement under the Securities Act of 1933. The Company will not receive any proceeds from the sale of the shares but will pay the expenses of the offering.
Regenerative medicine company Mesoblast Limited today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular Age-related Macular Degeneration.
Parents of very premature babies are more worried about their grown up children's lives than mothers and fathers whose babies were born full term.
Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.
VeriChip Corporation and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing development partnership with RECEPTORS to launch Phase II development of an in vivo glucose-sensing RFID microchip.
› Verified 8 days ago
| Entity Name | West Virginia University Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275504508 PECOS PAC ID: 1052224565 Enrollment ID: O20031111000207 |
News Archive
Warner Chilcott plc today announced a 20,000,000 share secondary offering of its ordinary shares by certain selling shareholders. The selling shareholders include funds affiliated with Bain Capital Partners, DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP Capital) and Thomas H. Lee Partners, L.P., certain other institutional investors and members of the Company's senior management. The offering is being conducted as a public offering pursuant to an effective shelf registration statement under the Securities Act of 1933. The Company will not receive any proceeds from the sale of the shares but will pay the expenses of the offering.
Regenerative medicine company Mesoblast Limited today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular Age-related Macular Degeneration.
Parents of very premature babies are more worried about their grown up children's lives than mothers and fathers whose babies were born full term.
Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.
VeriChip Corporation and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing development partnership with RECEPTORS to launch Phase II development of an in vivo glucose-sensing RFID microchip.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kimberly Hamilton, MD 1 Medical Center Dr, Morgantown, WV 26506-1200 Ph: () - | Dr Kimberly Hamilton, MD 1 Medical Center Dr, Morgantown, WV 26506-1200 Ph: (304) 598-6127 |
News Archive
Warner Chilcott plc today announced a 20,000,000 share secondary offering of its ordinary shares by certain selling shareholders. The selling shareholders include funds affiliated with Bain Capital Partners, DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP Capital) and Thomas H. Lee Partners, L.P., certain other institutional investors and members of the Company's senior management. The offering is being conducted as a public offering pursuant to an effective shelf registration statement under the Securities Act of 1933. The Company will not receive any proceeds from the sale of the shares but will pay the expenses of the offering.
Regenerative medicine company Mesoblast Limited today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular Age-related Macular Degeneration.
Parents of very premature babies are more worried about their grown up children's lives than mothers and fathers whose babies were born full term.
Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.
VeriChip Corporation and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing development partnership with RECEPTORS to launch Phase II development of an in vivo glucose-sensing RFID microchip.
› Verified 8 days ago
Dr. Jesse Lawrence, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: One Medical Center Dr, Department Of Neurosurgery, Suite 4300, Morgantown, WV 26506 Phone: 304-598-2905 Fax: 304-598-6130 | |
Louisa Onyewadume, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Morgantown, WV 26506 Phone: 304-598-6127 Fax: 304-598-6248 | |
Dr. Joseph Voelker, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Stadium Drive, Morgantown, WV 26506 Phone: 304-598-4800 Fax: 304-293-6963 | |
Dr. Cesar Augusto Serrano Almeida, M.D., FRCSC Neurological Surgery Medicare: Medicare Enrolled Practice Location: 1 Stadium Dr, Morgantown, WV 26506 Phone: 304-293-5041 | |
Dr. Ronald Hargraves, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Stadium Drive, Morgantown, WV 26506 Phone: 304-598-4800 Fax: 304-293-6963 | |
Dr. Bengt Karlsson, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1 Stadium Drive, Morgantown, WV 26506 Phone: 304-598-4800 Fax: 304-293-6963 |